Developer docs
API playgroundTry for free, no card

Search company profiles

KGK Science

Full company profile

uuid000bj7q

Namestring
KGK Science
Legal namestring
KGK Science Inc.
Websiteurl
kgkscience.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

KGK Science Inc. is a privately held Canadian contract research organization (CRO) founded in 1997 and headquartered in London, Ontario. It operates a premium clinical research and regulatory services model targeting nutraceutical, dietary supplement, food ingredient, cannabis, hemp, and psychedelic product companies, with disclosed operations across Canada, the United States, and Indonesia. The company is led by President & CEO Najla Guthrie, with regulatory leadership provided by Chief Regulatory Officer Corey Hilmas (former FDA regulator and co-author of the FDA's NDI draft guidance).

The firm's core product suite is organized into four pillars: Premium Clinical Trials™ (customized end-to-end or modular clinical trial services), Innovative Virtual Trials comprising PRO-VT™ (participant-reported outcomes) and C-VT™ (customized virtual trials with biological sample collection and wearable integration), Expert Regulatory Services spanning NDI notifications, GRAS conclusions, Health Canada PLAs, and regulatory strategy consulting, and Preclinical Studies covering toxicology, genotoxicity, and in vivo efficacy work. Underlying technology includes GCP-trained clinical operations, proprietary trial methodologies (Augmented RCT©), the CNS Vital Signs computerized cognitive testing battery, and the Cognalyzer® EEG-based objective test for cannabis impairment. The firm maintains a 45,000+ participant recruitment database and claims operational experience across 40+ therapeutic indications and hundreds of regulatory projects.

KGK operates as a B2B professional services business, generating revenue through fee-for-service clinical trial projects, regulatory consulting engagements, and preclinical study contracts. Pricing is quote-based and project-specific, reflecting trial scope, duration, sample size, and regulatory pathway; contracts range from short virtual studies to multi-year, multi-trial collaborations with enterprise sponsors (BioNeutra, AIDP, Unigen, Hofseth BioCare) alongside mid-market and startup clients. Go-to-market is direct B2B sales anchored on a website inquiry form and "Request Proposal" CTA, supplemented by thought leadership (white papers, peer-reviewed publications, The Orange Pill Podcast, monthly newsletter, press releases) and a parallel participant recruitment funnel. The company is founder/management-led with no disclosed venture capital or private equity backing.

Short descriptiontext

KGK Science is a privately held Canadian contract research organization founded in 1997 that provides clinical trial design, virtual trial execution, regulatory consulting, and preclinical services to nutraceutical, cannabis, hemp, and psychedelic product companies in North America and Indonesia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, Canada
HQ citystring
London
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, nutraceutical CRO, regulatory consulting, virtual clinical trials, preclinical studies
Industry1 code
PRIMARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Revenue model3 records
1Clinical Trial Services
TypeProfessional Services
Description

KGK Science generates revenue by providing fee-for-service clinical trial research projects to nutraceutical, dietary supplement, cannabis, and related companies. Services are project-based, ranging from end-to-end comprehensive trial management to specific research service modules, billed according to scope, duration, and complexity of the study.

kgkscience.com
2Regulatory Consulting Services
TypeProfessional Services
Description

Revenue is generated through regulatory consulting engagements including NDI notifications, GRAS conclusions, Health Canada Product License Applications (PLAs), regulatory status reviews, gap assessments, toxicology reviews, SOP creation, label reviews, and pharmacovigilance services. These are billed as discrete consulting projects or retainer engagements.

kgkscience.com
3Preclinical Studies
TypeProfessional Services
Description

Fees for preclinical safety and efficacy studies including genotoxicity batteries, LD50 testing, repeat-dose toxicity studies, reproductive toxicology, ADME/PK studies, neurobehavioral studies, and in vivo animal efficacy models.

kgkscience.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details2 tiers
1Participant compensation varies by study type and duration
ModelOtherBilling cadencePay-as-you-go
Notes

Clinical trial participants receive compensation ranging from $200 (short virtual studies) to $1,500 (complex PK studies requiring extended clinic stays and multiple blood draws). Examples: Perimenopausal Hot Flashes virtual trial $200; Stress patch study $400; Blood glucose control study $400; L-Theanine cognitive study $400; Women's digestive discomfort study $500; Focusing cognitive study $600; Memory and Omega-3 study $600; Cancer-related fatigue study up to $600; Diabetes study $600; Healthy aging patch study $600; Memory through digestion study $700; Hydration and exercise PK study $800; Menopausal symptoms pollen extract study $800; Abnormal Pap smear study $1,000; Hydrolyzed collagen blood sugar study $1,000; Children's probiotic immune health study $1,000; CoQ10 PK study $1,500; Everyday research PG study $1,500.

kgkscience.com
2B2B service pricing is quote-based and project-specific
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly disclosed pricing for sponsor/CRO services. Contact-based pricing through Request Proposal or direct sponsor inquiry form. Services include Premium Clinical Trials™, Innovative Virtual Trials, Expert Regulatory Services, and Preclinical Studies.

kgkscience.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KGK Science is a premium contract research organization that designs and runs customized clinical trials (including virtual PRO-VT™ and C-VT™ formats) for nutraceutical, dietary supplement, cannabis, hemp, and psychedelic product companies. It also provides comprehensive regulatory consulting (NDI notifications, GRAS conclusions, Health Canada Product License Applications, FDA 30-day structure-function submissions) and preclinical safety/efficacy testing. Services are available end-to-end or as scoped modules, with every project supported by GCP-trained clinical research staff and validated cognitive/biomarker assessment tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Successfully completed hundreds of regulatory projects including NDI notifications, GRAS conclusions, and Health Canada PLAs
+5 more records
Product overview1 text field

KGK Science operates as a premium Contract Research Organization (CRO) offering a comprehensive suite of clinical research and regulatory services for the nutraceutical, cannabis, hemp, and psychedelic industries. The core offerings include Premium Clinical Trials™ (end-to-end or specific clinical trial services), Innovative Virtual Trials comprising PRO-VT™ (participant-reported outcomes virtual trials) and C-VT™ (customized virtual trials), Expert Regulatory Services (NDI notifications, GRAS conclusions, Health Canada PLA submissions), and Preclinical Studies (toxicology and animal efficacy studies). The company also recruits participants for various health studies including cognitive health, women's health, gut health, stress/anxiety, diabetes/blood sugar, sleep, hydration, and pediatric studies.

Product and service5 records
1Premium Clinical Trials™
CategoryClinical Trial Services
Description

High-quality clinical trial research services offering customized trial design to enhance marketing claims, develop intellectual property, and distinguish brands. Provides end-to-end trial services or specific research services for nutraceutical, dietary supplement, cannabis, hemp, and psychedelic industry sponsors.

2PRO-VT™ (Participant Reported Outcomes Virtual Trials)
CategoryVirtual Clinical Trial Services
Description

Cost-effective virtual trial solution for nutraceutical validation using participant-reported outcomes, supporting sample sizes of 250, 500, or more participants. Meets HIPAA and 21 CFR Part 11 compliance, with optional Consumer Report Card and rapid executive reporting, designed for swift validation of dietary supplement efficacy claims.

3C-VT™ (Customized Virtual Trials)
CategoryVirtual Clinical Trial Services
Description

Remote clinical trials with rigorous, customized design meeting regulatory standards. Offers options for biological sample collection, wearable data devices, and hybrid in-clinic/virtual study models. Supports large sample sizes and expanded scope for diverse study needs among dietary supplement sponsors.

4Expert Regulatory Services
CategoryRegulatory Consulting
Description

Comprehensive regulatory support services including NDI notifications, GRAS conclusions, Health Canada product license applications (PLAs), regulatory status reviews, gap assessments, toxicology reviews, SOP creation, label reviews, and pharmacovigilance. Led by a former FDA regulator, supporting nutraceutical, cannabis, hemp, and psychedelic industry sponsors in FDA, Health Canada, and EFSA pathways.

5Preclinical Studies
CategoryPreclinical Research Services
Description

Preclinical safety and efficacy testing services including genotoxicity batteries, LD50 testing, repeat-dose toxicity studies, reproductive toxicology, ADME/PK studies, neurobehavioral studies, and in vivo animal efficacy models. Supports nutraceutical, food ingredient, and related product development by providing regulatory-grade preclinical evidence to support downstream clinical and regulatory submissions.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

KGK Science conducted a randomized, triple-blind, placebo-controlled clinical trial for Unigen evaluating Maizinol® on sleep quality. Results were published in the peer-reviewed journal Food Science & Nutrition, and significant findings were presented at Sleep 2025 and Nutrition 2025 conferences. This represents a multi-trial collaboration with publication outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

KGK Science entered a research services agreement to conduct a human clinical trial evaluating NAD+ Advanced, Cata-Kor's high-dose NAD+ nutraceutical ingredient, supporting the company's product development and regulatory pathway.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-03
Description

KGK Science successfully secured a Health Canada Class III Product License Application (PLA) for Qlarity™, supporting Lucid Psycheceuticals' successful path to market in Canada as a natural health product.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Health Canada approved a human clinical trial for Papillex®, a natural cervical health supplement developed by WELLEX in collaboration with Natural Products Canada, with KGK Science providing clinical trial services.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

KGK Science is collaborating with ATMA CENA on a clinical study investigating psilocybin-assisted therapy for Major Depressive Disorder in healthcare workers who worked during the COVID-19 pandemic.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Citranex Labs
TypeEmerging player
Description

Citranex Labs is a smaller contract research and testing provider for nutraceutical and food ingredient companies, an emerging player that overlaps with KGK's trial design and regulatory support offerings at a more limited scale.

TypeBroad incumbent
Description

SGS is a global testing, inspection, and certification company that supports food ingredient and nutraceutical companies with testing and regulatory services, serving as a broad incumbent comparable in end markets if not in trial management.

TypeBroad incumbent
Description

Eurofins is a global testing and CRO conglomerate with broad food, supplement, and pharmaceutical laboratory services; it is a broad incumbent offering overlapping capabilities (testing, regulatory) but as part of a much wider portfolio rather than a nutraceutical specialty.

TypeEmerging player
Description

Inotiv is a preclinical CRO with toxicology and animal model capabilities comparable to KGK's Preclinical Studies service (genotoxicity, ADME/PK, neurobehavioral, in vivo efficacy), although Inotiv is broader and pharma-oriented.

TypeBroad incumbent
Description

Worldwide Clinical Trials is a mid-to-large CRO with clinical and bioanalytical services; it is a broad incumbent relevant for sponsors considering scaling beyond KGK's nutraceutical specialty into general clinical development.

6CliniGlobal
TypeDirect peer
Description

CliniGlobal is a nutraceutical-focused CRO offering clinical trial management and regulatory support for dietary supplement and food ingredient companies, overlapping with KGK's Premium Clinical Trials™ and Expert Regulatory Services lines.

TypeBroad incumbent
Description

Intertek provides testing, inspection, and certification services including for food, dietary supplements, and pharmaceuticals, making it a broad incumbent that touches KGK's regulatory and quality service space but is not nutraceutical-trial focused.

TypeBroad incumbent
Description

Pharmaron is a global CRO/CDMO with preclinical, clinical, and regulatory services; it represents a broad incumbent competitor for KGK's preclinical and regulatory work, particularly for sponsors seeking end-to-end development support.

TypeBroad incumbent
Description

Charles River Laboratories is a major CRO with preclinical and clinical services; it is a broad incumbent relevant because KGK's preclinical service line and clinical operations compete for similar sponsor relationships, even though Charles River is much larger and more pharma-focused.

TypeDirect peer
Description

Vedic Lifesciences is a contract research organization that runs clinical trials specifically for nutraceutical, dietary supplement, and functional food companies — directly comparable to KGK Science's core service offering and target sponsor base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KGK Science

Contract Research Organization (CRO) Serviceskgkscience.com

KGK Science is a privately held Canadian contract research organization founded in 1997 that provides clinical trial design, virtual trial execution, regulatory consulting, and preclinical services to nutraceutical, cannabis, hemp, and psychedelic product companies in North America and Indonesia.

What KGK Science does

KGK Science Inc. is a privately held Canadian contract research organization (CRO) founded in 1997 and headquartered in London, Ontario. It operates a premium clinical research and regulatory services model targeting nutraceutical, dietary supplement, food ingredient, cannabis, hemp, and psychedelic product companies, with disclosed operations across Canada, the United States, and Indonesia. The company is led by President & CEO Najla Guthrie, with regulatory leadership provided by Chief Regulatory Officer Corey Hilmas (former FDA regulator and co-author of the FDA's NDI draft guidance).

The firm's core product suite is organized into four pillars: Premium Clinical Trials™ (customized end-to-end or modular clinical trial services), Innovative Virtual Trials comprising PRO-VT™ (participant-reported outcomes) and C-VT™ (customized virtual trials with biological sample collection and wearable integration), Expert Regulatory Services spanning NDI notifications, GRAS conclusions, Health Canada PLAs, and regulatory strategy consulting, and Preclinical Studies covering toxicology, genotoxicity, and in vivo efficacy work. Underlying technology includes GCP-trained clinical operations, proprietary trial methodologies (Augmented RCT©), the CNS Vital Signs computerized cognitive testing battery, and the Cognalyzer® EEG-based objective test for cannabis impairment. The firm maintains a 45,000+ participant recruitment database and claims operational experience across 40+ therapeutic indications and hundreds of regulatory projects.

KGK operates as a B2B professional services business, generating revenue through fee-for-service clinical trial projects, regulatory consulting engagements, and preclinical study contracts. Pricing is quote-based and project-specific, reflecting trial scope, duration, sample size, and regulatory pathway; contracts range from short virtual studies to multi-year, multi-trial collaborations with enterprise sponsors (BioNeutra, AIDP, Unigen, Hofseth BioCare) alongside mid-market and startup clients. Go-to-market is direct B2B sales anchored on a website inquiry form and "Request Proposal" CTA, supplemented by thought leadership (white papers, peer-reviewed publications, The Orange Pill Podcast, monthly newsletter, press releases) and a parallel participant recruitment funnel. The company is founder/management-led with no disclosed venture capital or private equity backing.

KGK Science firmographics

Firmographics
Name
KGK Science
Legal name
KGK Science Inc.
Website
https://kgkscience.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
KGK Science is a privately held Canadian contract research organization founded in 1997 that provides clinical trial design, virtual trial execution, regulatory consulting, and preclinical services to nutraceutical, cannabis, hemp, and psychedelic product companies in North America and Indonesia.
Ownership category
akta.pro rank

KGK Science industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Clinical research services
  • Nutraceutical CRO
  • Regulatory consulting
  • Virtual clinical trials
  • Preclinical studies

Where KGK Science is headquartered

Location

Headquarters

HQ city
London
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

KGK Science business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Clinical Trial Services: KGK Science generates revenue by providing fee-for-service clinical trial research projects to nutraceutical, dietary supplement, cannabis, and related companies. Services are project-based, ranging from end-to-end comprehensive trial management to specific research service modules, billed according to scope, duration, and complexity of the study.
  2. Regulatory Consulting Services: Revenue is generated through regulatory consulting engagements including NDI notifications, GRAS conclusions, Health Canada Product License Applications (PLAs), regulatory status reviews, gap assessments, toxicology reviews, SOP creation, label reviews, and pharmacovigilance services. These are billed as discrete consulting projects or retainer engagements.
  3. Preclinical Studies: Fees for preclinical safety and efficacy studies including genotoxicity batteries, LD50 testing, repeat-dose toxicity studies, reproductive toxicology, ADME/PK studies, neurobehavioral studies, and in vivo animal efficacy models.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goParticipant compensation varies by study type and duration
OtherMulti-year contractB2B service pricing is quote-based and project-specific

Distribution channels2 records

Marketing channels7 records

KGK Science product offering

Product offering

Core offering

KGK Science is a premium contract research organization that designs and runs customized clinical trials (including virtual PRO-VT™ and C-VT™ formats) for nutraceutical, dietary supplement, cannabis, hemp, and psychedelic product companies. It also provides comprehensive regulatory consulting (NDI notifications, GRAS conclusions, Health Canada Product License Applications, FDA 30-day structure-function submissions) and preclinical safety/efficacy testing. Services are available end-to-end or as scoped modules, with every project supported by GCP-trained clinical research staff and validated cognitive/biomarker assessment tools.

Product overview

KGK Science operates as a premium Contract Research Organization (CRO) offering a comprehensive suite of clinical research and regulatory services for the nutraceutical, cannabis, hemp, and psychedelic industries. The core offerings include Premium Clinical Trials™ (end-to-end or specific clinical trial services), Innovative Virtual Trials comprising PRO-VT™ (participant-reported outcomes virtual trials) and C-VT™ (customized virtual trials), Expert Regulatory Services (NDI notifications, GRAS conclusions, Health Canada PLA submissions), and Preclinical Studies (toxicology and animal efficacy studies). The company also recruits participants for various health studies including cognitive health, women's health, gut health, stress/anxiety, diabetes/blood sugar, sleep, hydration, and pediatric studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Premium Clinical Trials™ High-quality clinical trial research services offering customized trial design to enhance marketing claims, develop intellectual property, and distinguish brands. Provides end-to-end trial services or specific research services for nutraceutical, dietary supplement, cannabis, hemp, and psychedelic industry sponsors.
  • PRO-VT™ (Participant Reported Outcomes Virtual Trials) Cost-effective virtual trial solution for nutraceutical validation using participant-reported outcomes, supporting sample sizes of 250, 500, or more participants. Meets HIPAA and 21 CFR Part 11 compliance, with optional Consumer Report Card and rapid executive reporting, designed for swift validation of dietary supplement efficacy claims.
  • C-VT™ (Customized Virtual Trials) Remote clinical trials with rigorous, customized design meeting regulatory standards. Offers options for biological sample collection, wearable data devices, and hybrid in-clinic/virtual study models. Supports large sample sizes and expanded scope for diverse study needs among dietary supplement sponsors.
  • Expert Regulatory Services Comprehensive regulatory support services including NDI notifications, GRAS conclusions, Health Canada product license applications (PLAs), regulatory status reviews, gap assessments, toxicology reviews, SOP creation, label reviews, and pharmacovigilance. Led by a former FDA regulator, supporting nutraceutical, cannabis, hemp, and psychedelic industry sponsors in FDA, Health Canada, and EFSA pathways.
  • Preclinical Studies Preclinical safety and efficacy testing services including genotoxicity batteries, LD50 testing, repeat-dose toxicity studies, reproductive toxicology, ADME/PK studies, neurobehavioral studies, and in vivo animal efficacy models. Supports nutraceutical, food ingredient, and related product development by providing regulatory-grade preclinical evidence to support downstream clinical and regulatory submissions.

Quantifiable outcome

  • Successfully completed hundreds of regulatory projects including NDI notifications, GRAS conclusions, and Health Canada PLAs
  • +5 more outcomes

Companies that use KGK Science

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles4 records

KGK Science technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

KGK Science partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Unigen Inc.coreStrategic or Co-development Partner · 6 January 2026KGK Science conducted a randomized, triple-blind, placebo-controlled clinical trial for Unigen evaluating Maizinol® on sleep quality. Results were published in the peer-reviewed journal Food Science & Nutrition, and significant findings were presented at Sleep 2025 and Nutrition 2025 conferences. This represents a multi-trial collaboration with publication outcomes.
  • Cata-KorcoreStrategic or Co-development Partner · 23 October 2025KGK Science entered a research services agreement to conduct a human clinical trial evaluating NAD+ Advanced, Cata-Kor's high-dose NAD+ nutraceutical ingredient, supporting the company's product development and regulatory pathway.
  • Lucid PsycheceuticalscoreStrategic or Co-development Partner · 3 October 2025KGK Science successfully secured a Health Canada Class III Product License Application (PLA) for Qlarity™, supporting Lucid Psycheceuticals' successful path to market in Canada as a natural health product.
  • WELLEX / Natural Products CanadacoreStrategic or Co-development Partner · 1 July 2025Health Canada approved a human clinical trial for Papillex®, a natural cervical health supplement developed by WELLEX in collaboration with Natural Products Canada, with KGK Science providing clinical trial services.
  • ATMA CENAminorStrategic or Co-development Partner · 1 June 2025KGK Science is collaborating with ATMA CENA on a clinical study investigating psilocybin-assisted therapy for Major Depressive Disorder in healthcare workers who worked during the COVID-19 pandemic.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

KGK Science competitors and assessment

Company assessment

Emerging players

  • Citranex Labs: Citranex Labs is a smaller contract research and testing provider for nutraceutical and food ingredient companies, an emerging player that overlaps with KGK's trial design and regulatory support offerings at a more limited scale.
  • Inotiv: Inotiv is a preclinical CRO with toxicology and animal model capabilities comparable to KGK's Preclinical Studies service (genotoxicity, ADME/PK, neurobehavioral, in vivo efficacy), although Inotiv is broader and pharma-oriented.

Broad incumbents

  • SGS: SGS is a global testing, inspection, and certification company that supports food ingredient and nutraceutical companies with testing and regulatory services, serving as a broad incumbent comparable in end markets if not in trial management.
  • Eurofins Scientific: Eurofins is a global testing and CRO conglomerate with broad food, supplement, and pharmaceutical laboratory services; it is a broad incumbent offering overlapping capabilities (testing, regulatory) but as part of a much wider portfolio rather than a nutraceutical specialty.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-to-large CRO with clinical and bioanalytical services; it is a broad incumbent relevant for sponsors considering scaling beyond KGK's nutraceutical specialty into general clinical development.
  • Intertek: Intertek provides testing, inspection, and certification services including for food, dietary supplements, and pharmaceuticals, making it a broad incumbent that touches KGK's regulatory and quality service space but is not nutraceutical-trial focused.
  • Pharmaron: Pharmaron is a global CRO/CDMO with preclinical, clinical, and regulatory services; it represents a broad incumbent competitor for KGK's preclinical and regulatory work, particularly for sponsors seeking end-to-end development support.
  • Charles River Laboratories: Charles River Laboratories is a major CRO with preclinical and clinical services; it is a broad incumbent relevant because KGK's preclinical service line and clinical operations compete for similar sponsor relationships, even though Charles River is much larger and more pharma-focused.

Direct peers

  • CliniGlobal: CliniGlobal is a nutraceutical-focused CRO offering clinical trial management and regulatory support for dietary supplement and food ingredient companies, overlapping with KGK's Premium Clinical Trials™ and Expert Regulatory Services lines.
  • Vedic Lifesciences: Vedic Lifesciences is a contract research organization that runs clinical trials specifically for nutraceutical, dietary supplement, and functional food companies — directly comparable to KGK Science's core service offering and target sponsor base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

KGK Science social profiles

Digital presence

KGK Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KGK Science leadership team

Management profile

Number of profiles

Profiles3 records

KGK Science funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KGK Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KGK Science

What does KGK Science do?

KGK Science is a premium contract research organization that designs and runs customized clinical trials (including virtual PRO-VT™ and C-VT™ formats) for nutraceutical, dietary supplement, cannabis, hemp, and psychedelic product companies. It also provides comprehensive regulatory consulting (NDI notifications, GRAS conclusions, Health Canada Product License Applications, FDA 30-day structure-function submissions) and preclinical safety/efficacy testing. Services are available end-to-end or as scoped modules, with every project supported by GCP-trained clinical research staff and validated cognitive/biomarker assessment tools.

Is KGK Science a public or private company?

KGK Science is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was KGK Science founded?

KGK Science was founded in 1997. It employs 51 to 100 people.

Where is KGK Science based?

KGK Science is headquartered in London, Canada, in the North America region.

How does KGK Science make money?

Three revenue lines are on record. Clinical Trial Services are the primary driver. The others are regulatory Consulting Services and preclinical Studies.

Who are KGK Science's main competitors?

Emerging players on record are Citranex Labs and Inotiv. Broad incumbents are SGS, Eurofins Scientific, Worldwide Clinical Trials, Intertek, Pharmaron and Charles River Laboratories. Direct peers are CliniGlobal and Vedic Lifesciences.

Does KGK Science have an API?

No public API is recorded for KGK Science.

What industry is KGK Science in?

KGK Science's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAFAN, Nonclinical Study Management & Regulatory Writing (IND-enabling). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsKGK Science Receives Growth Investment From Maxim PartnersKGK Science Inc., a London, Ontario-based contract research organization specializing in nutraceuticals and natural health products, received a growth investment from Maxim Partners. The funding will support expanded clinical trial capacity, decentralized and virtual trial capabilities, regulatory services growth, and commercial organization expansion. Founded in 1997 and led by CEO Najla Guthrie, the company has completed over 400 clinical trials across more than 40 health indications and published over 150 peer-reviewed scientific publications.Private Capital JournalMaxim Partners invests in KGK ScienceKGK Science Inc., a London, Ontario-based contract research organization specializing in clinical trials for dietary supplements and nutraceuticals, has received a growth investment from Chicago-based private equity firm Maxim Partners, with the transaction closing on June 30, 2026. The investment will support expanded clinical trial capacity, decentralized and virtual trial capabilities, and growth of the company's regulatory services, while Founder and CEO Najla Guthrie and the existing management team continue to lead the business. Founded in 1997, KGK has completed over 400 clinical trials across more than 40 health indications and published over 150 peer-reviewed scientific publications, positioning it as a leading North American CRO in the consumer health sector.NewswireKGK Science Receives Growth Investment Led by Maxim PartnersKGK Science received a growth investment led by Maxim Partners, closing on June 30, 2026. Financial terms were not disclosed. The investment will support expanded clinical trial capacity, decentralized trial capabilities, regulatory services, and commercial growth.MorningstarKGK Science Receives Growth Investment Led by Maxim PartnersKGK Science received a growth investment led by Maxim Partners, closing on June 30, 2026. Financial terms were not disclosed. The investment will support expanded clinical trial capacity, decentralized trial capabilities, and regulatory services growth.PR NewswireKGK Science Receives Growth Investment Led by Maxim PartnersKGK Science received a growth investment led by Maxim Partners, closing June 30, 2026, with financial terms undisclosed. The investment will support expanded clinical trial capacity, decentralized trial capabilities, regulatory services, and commercial growth. KGK, founded in 1997, has completed over 400 clinical trials across 40+ health indications.PR NewswireHealth Research Ethics Board of Alberta Approves ATMA's Phase II Psilocybin Clinical Trial with Group and Individual Therapy SettingsATMA Journey Centers Inc., a Canadian psychedelic therapy company, has received approvals from the Health Research Ethics Board of Alberta and Health Canada for its Phase II psilocybin-assisted therapy clinical trial targeting frontline mental healthcare professionals with Major Depressive Disorder, incorporating both group and individual therapy settings. The trial will be Canada's largest Phase II psilocybin-assisted therapy study, conducted across three sites in Calgary, London, and Vancouver in partnership with KGK Science and psychedelic group therapy experts. The company aims to evaluate psilocybin therapy efficacy while exploring a novel group protocol that could enhance accessibility and affordability of mental health treatment for healthcare workers.YahooPredictmedix AI and KGK Science Partner to Enhance Health Research and Product DevelopmentPredictmedix AI and KGK Science announced a partnership to integrate Predictmedix's AI health screening into KGK's clinical trials. The collaboration aims to improve trial efficiency and reduce costs for research organizations. The alliance targets new operational verticals in health research and product development.GlobeNewswireBetter Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement for PetsBetter Choice and Aimia Pet HealthCo signed an MOU with KGK Science to develop a GLP1 supplement for pets. The supplement will be combined with Halo branded toppers or treats to treat obesity in dogs and cats, as over half of dogs and cats worldwide are overweight or obese.BioSpaceWellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical TrialKGK Sciences submitted a clinical trial application for a Phase IIa study of psilocybin microdose for Fragile X syndrome, with Health Canada's 30-day review pending. The open-label 10-patient study would support Nova Mentis' orphan drug designation and aim to start in early 2023.GlobeNewswireMyconic Capital to Acquire KGK Science From Auxly Cannabis GroupMyconic Capital Corp. has entered into a definitive agreement to acquire 100% of KGK Science Inc. from Auxly Cannabis Group for a base consideration of $12.5 million payable in cash and shares. The transaction, which includes a milestone payment structure and a service credit for Auxly, is expected to close in early June 2021 pending NEO Exchange approval. Myconic intends to expand KGK's clinical research services to include psychedelic drugs, aligning with its strategic focus on mental health.